Neurological aspects of HIV/human T lymphotropic virus coinfection

AIDS Reviews

Volumn 11, Issue 2, 2009, Pages 71-78

  Silva, Marcus Tulius ^a   de Melo Espíndola, Otávio ^a   Bezerra Leite, Ana Cláudia C ^a   Araújo, Abelardo ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

ATL; Coinfection; HAM TSP; HTLV 1; HTLV 2; tHIV

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CXCR4; LAMIVUDINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PLACEBO; REV PROTEIN; TAX PROTEIN; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; COGNITIVE DEFECT; DISEASE PREDISPOSITION; HIGH RISK PATIENT; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; MIXED INFECTION; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NONHUMAN; PERIPHERAL NEUROPATHY; REVIEW; SKIN LYMPHOMA; SPINAL CORD DISEASE; VIRUS CELL INTERACTION; VIRUS EXPRESSION; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

EID: 70049093131     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Poiesz B, Ruscetti F, Gazoar A, Bunn P, Minna J, Gallo R. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA. 1980;77:7415-9.
2. Kalyanaraman V, Sarngadharan M, Robert-Guroff M, Miyoshi I, Golde D, Gallo R. A new subtype of HTLV-2 associated with a T-cell variant of hairy cell leukemia. Science. 1982;218:571-3.
3. Osame M, Usuku K, Izumo S. HTLV-1 associated myelopathy, a new clinical entity. Lancet. 1986;1:1031-2.
4. Araujo A, Silva M. The HTLV-1 neurological complex. Lancet Neurol. 2006;5:1068-76.
5. Silva M, Harab R, Leite A, Schor D, Araujo A, Andrada-Serpa M. Human T lymphotropic virus type 1 (HTLV-1) proviral load in asymptomatic carriers, HTLV-1-associated myelopathy/tropical spastic paraparesis, and other neurological abnormalities associated with HTLV-1 infection. Clin Infect Dis. 2007;44:689-92.
6. Nagai M, Usuku K, Matsumoto W, et al. Analysis of HTLV-1 proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-1 carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol. 1998;4:586-93.
7. Price R, Brew B, Sidtis J, Rosenblum M, Scheck A, Cleary P. The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science. 1988;239:586-92.
8. Silva M, Araujo A. Highly active antiretroviral therapy access and neurological complications of HIV infection: impact versus resources in Brazil. J Neurovirol. 2005;11(Suppl 3):11-5.
9. Johnson J, Franchini G. Retroviral proteins that target the major histocompatibility complex class I. Virus Res. 2002;88:119-27.
10. Bindhu M, Nair A, Lairmore M. Role of accessory proteins of HTLV-1 in viral replication, T cell activation, and cellular gene expression. Front Biosci. 2004;9:2556-76.
11. Sierra S, Kupfer B, Kaiser R. Basics of the virology of HIV-1 and its replication. J Clin Virol. 2005;34:233-44.
12. Fan N, Gavalchin J, Paul B, Wells K, Lane M, Poiesz B. Infection of peripheral blood mononuclear cells and cell lines by cell-free HTLV-1. J Clin Microbiol. 1992;30:905-10.
13. Roy U, Simpson S, Mondal D, Eloby-Childress S, Winsor E, Beilke M. Upregulation of HTLV-1 and HTLV-2 expression by HIV-1 in vitro. J Med Virol. 2008;80:494-500.
14. Kubota S, Furuta R, Hatanaka M, Pomerantz R. Modulation of HTLV-1 gene expression by HIV-1 Rev through an alternative RxRE-independent pathway mediated by the RU5 portion of the 5′-LTR. Biochem Biophys Res Commun. 1998;243:79-85.
15. Beilke M, Japa S, Vinson D. HTLV-1 and HTLV-2 virus expression increase with HIV-1 coinfection. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17:391-7.
16. De Rossi A, Saggioro D, Calabro M, Cenzato R, Chieco-Bianchi L. Reciprocal activation of human T-lymphotropic viruses in HTLV-1-transformed cells superinfected with HIV-1. J Acquir Immune Defic Syndr. 1991;4:380-5.
17. Olah I, Fukumori L, Montanheiro P, et al. Patterns of in vitro lymphoproliferative responses among HTLV-1-infected subjects: upregulation by HTLV-1 during HIV-1 coinfection. Scand J Immunol. 2007;65:577-80.
18. Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient HIV replication in mobile lymphocytes. J Virol. 2007;81:1000-12.
19. Jolly C, Kashefi K, Hollinshead M, Sattentau Q. HIV-1 cell to cell transfer across an Env-induced, actin-dependent synapse. J Exp Med. 2004;199:283-93.
20. Jolly C, Sattentau Q. Retroviral spread by induction of virologic synapses. Traffic. 2004;5:643-50.
21. Stebbing J, Gazzard B, Douek D. Where does HIV live? N Engl J Med. 2004;350:1872-80.
22. Kazanji M, Ureta-Vidal A, Ozden S, et al. Lymphoid organs as a major reservoir for HTLV-1 in experimentally infected squirrel monkeys (Saimiri sciureus): provirus expression, persistence, and humoral and cellular immune responses. J Virol. 2000;74:4860-7.
23. Takenouchi N, Matsuoka E, Moritoyo T, et al. Molecular pathologic analysis of the tonsil in HTLV-1-infected individuals. J Acquir Immune Defic Syndr. 1999;22:200-7.
24. Bangham C. The immune control and cell-to-cell spread of HTLV-1. J Gen Virol. 2003;84:3177-89.
25. Igakura T, Stinchcombe J, Goon P, et al. Spread of HTLV-1 between lymphocytes by virus-induced polarization of the cytoskeleton. Science. 2003;299:1713-6.
26. Sun J, Barbeau B, Tremblay M. HIV-1-mediated syncytium formation promotes cell-to-cell transfer of Tax protein and HTLV-1 gene expression. Virus Res. 2006;118:120-9.
27. Casoli C, Vicenzi E, Cimarelli A, et al. HTLV-2 downregulates HIV-1 replication in IL-2-stimulated primary PBMC of coinfected individuals through expression of MIP-1alpha. Blood. 2000;95:2760-9.
28. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science. 1993;261:1179-81.
29. Berger E, Doms R, Fenyo E, et al. A new classification for HIV-1. Nature. 1998;391:240.
30. Connor R, Sheridan K, Ceradini D, Choe S, Landau N. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-8.
31. Scarlatti G, Tresoldi E, Bjorndal A, et al. In vivo evolution of HIV-1 coreceptor usage and sensitivity to chemokine-mediated suppression. Nat Med. 1997;3:1259-65.
32. Biddison W, Kubota R, Kawanishi T, et al. Human T cell leukemia virus type 1 (HTLV-1)-specific CD8+ CTL clones from patients with HTLV-1-associated neurologic disease secrete proinflammatory cytokines, chemokines, and matrix metalloproteinase. J Immunol. 1997; 159:2018-25.
33. Moriuchi H, Moriuchi M, Fauci A. Factors secreted by HTLV-1-infected cells can enhance or inhibit replication of HIV-1 in HTLV-1-uninfected cells: implications for in vivo coinfection with HTLV-1 and HIV-1. J Exp Med. 1998;187:1689-97.
34. Nyland S, Specter S, Ugen K. Morphine effects on HTLV-1 infection in the presence or absence of concurrent HIV-1 infection. DNA Cell Biol. 1999;18:285-91.
35. Szabo J, Beck Z, Csoman E, et al. Differential patterns of interaction between HIV-1 and HTLV-I in monocyte-derived macrophages cultured in vitro: implications for in vivo coinfection with HIV-1 and HTLV-I. AIDS Res Hum Retroviruses. 1999;15:1653-66.
36. Bassani S, Lopez M, Toro C, et al. Influence of HTLV-2 coinfection on virologic and immunological parameters in HIV type 1-infected patients. Clin Infect Dis. 2007;44:105-10.
37. Casseb J, Posada-Vergara M, Montanheiro P, et al. T CD4+ cells count among patients coinfected with HIV-1 and HTLV-1: high prevalence of tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM). Rev Inst Med Trop Sao Paulo. 2007;49:231-3.
38. Schechter M, Moulton L, Harrison L. HIV viral load and CD4+ lymphocyte counts in subjects coinfected with HTLV-1 and HIV-1. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;15:308-11.
39. Bovolenta C, Pilotti E, Mauri M, et al. Human T-cell leukemia virus type 2 induces survival and proliferation of CD34(+) TF-1 cells through activation of STAT1 and STAT5 by secretion of interferongamma and granulocyte macrophage-colony-stimulating factor. Blood. 2002;99:224-31.
40. Afonso P, Ozden S, Cumont M, et al. Alteration of blood-brain barrier integrity by retroviral infection. PLoS Pathog. 2008;4:e1000205.
41. Lehky T, Fox C, Koenig S, et al. Detection of HTLV-1 tax RNA in the central nervous system of HTLV-1-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol. 1995;37:167-75.
42. Mor-Vaknin N, Turgeman H, Torgeman A, Wolfson M, Huleihel M, Aboud M. Rapid syncytium formation between HTLV-1-infected T-cells and human nervous system cells: a possible implication for tropical spastic paraparesis/HTLV-1 associated myelopathy. Cell Biol Int. 1998;22:95-103.
43. Barcia C, Sanderson N, Barrett R, et al. T cells' immunological synapses induce polarization of brain astrocytes in vivo and in vitro: a novel astrocyte response mechanism to cellular injury. PLoS ONE. 2008;3:e2977.
44. Wang H, Sun J, Goldstein H. HIV-1 infection increases the in vivo capacity of peripheral monocytes to cross the blood-brain barrier into the brain and the in vivo sensitivity of the blood-brain barrier to disruption by lipopolysaccharide. J Virol. 2008;82:7591-600.
45. Shieh J, Martin J, Baltuch G, Malim M, Gonzalez-Scarano F. Determinants of syncytium formation in microglia by HIV-1: role of the V1/V2 domains. J Virol. 2000;74:693-701.
46. Alexaki A, Liu Y, Wigdahl B. Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res. 2008;6:388-400.
47. Levin M, Rosenblum M, Fox C, Jacobson S. Localization of retrovirus in the central nervous system of a patient coinfected with HTLV-1 and HIV with HAM/TSP and HIV-associated dementia. J Neurovirol. 2001;7:61-5.
48. Cesaire R, Dehee A, Lezin A, et al. Quantification of HTLV type 1 and HIV type 1 DNA load in coinfected patients: HIV type 1 infection does not alter HTLV type 1 proviral amount in the peripheral blood compartment. AIDS Res Hum Retroviruses. 2001;17:799-805.
49. Woods T, Graber J, Hershow R, Khabbaz R, Kaplan J, Heneine W. Investigation of proviral load in individuals infected with HTLV-2. AIDS Res Hum Retroviruses. 1995;11:1235-9.
50. Machuca A, Soriano V. In vivo fluctuation of HTLV-1 and HTLV-2 proviral load in patients receiving antiretroviral drugs. J Acquir Immune Defic Syndr. 2000;24:189-93.
51. Turci M, Pilotti E, Ronzi P, et al. Coinfection with HIV-1 and human T-Cell lymphotropic virus type II in intravenous drug users is associated with delayed progression to AIDS. J Acquir Immune Defic Syndr. 2006;41:100-6.
52. Orland J, Engstrom J, Fridey J, et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology. 2003;61:1588-94.
53. Poiesz B, Dube D, Dube S, et al. HTLV-2-associated cutaneous T-cell lymphoma in a patient with HIV-1 infection. N Engl J Med. 2000; 342:930-6.
54. Dooneief G, Marlink R, Bell K, et al. Neurologic consequences of HTLV-2 infection in injection-drug users. Neurology. 1996;46:1556-60.
55. Zehender G, Colasante C, De Maddalena C, et al. High prevalence of HTLV-1 in immigrant male-to-female transsexual sex workers with HIV-1 infection. J Med Virol. 2004;74:207-15.
56. Zehender G, Colasante C, Santambrogio S, et al. Increased risk of developing peripheral neuropathy in patients coinfected with HIV-1 and HTLV-2. J Acquir Immune Defic Syndr. 2002;31:440-7.
57. Araujo A, Leite A, Dultra S, Andrada-Serpa M. Progression of neurological disability in HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP). J Neurol Sci. 1995;129:147-51.
58. Takenouchi N, Yamano Y, Usuku K, Osame M, Izumo S. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with HTLV-1-associated myelopathy/tropical spastic paraparesis. J Neurovirol. 2003;9:29-35.
59. Araujo A, Hall W. Human T-lymphotropic virus type II and neurological disease. Ann Neurol. 2004;56:10-9.
60. Dal Pan G, Glass J, McArthur J. Clinicopathologic correlations of HIV-1-associated vacuolar myelopathy: an autopsy-based case-control study. Neurology. 1994;44:2159-64.
61. Harrison L, Vaz B, Taveira D, et al. Myelopathy among Brazilians coinfected with HTLV-1 and HIV. Neurology. 1997;48:13-8.
62. Beilke M, Japa S, Moeller-Hadi C, Martin-Schild S. Tropical spastic paraparesis/human T leukemia virus type 1-associated myelopathy in HIV type 1-coinfected patients. Clin Infect Dis. 2005;41:e57-63.
63. Posada-Vergara M, Montanheiro P, Fukumori L, et al. Clinical and epidemiological aspects of HTLV-2 infection in Sao Paulo, Brazil: presence of tropical spastic paraparesis/HTLV-associated myelopathy (TSP/ HAM) simile diagnosis in HIV-1-co-infected subjects. Rev Inst Med Trop Sao Paulo. 2006;48:207-10.
64. Montgomery R, Cruickshank J, Robertson W, McMenemey W. Clinical and pathological observations on Jamaican neuropathy. A report on 206 cases. Brain. 1964;87:425-62.
65. Barkhaus P, Morgan O. Jamaican neuropathy: an electrophysiological study. Muscle Nerve. 1988;11:380-5.
66. Roman G, Roman L. Tropical spastic paraparesis. A clinical study of 50 patients from Tumaco (Colombia) and review of the worldwide features of the syndrome. J Neurol Sci. 1988;87:121-38.
67. Leite A, Silva M, Alamy A, et al. Peripheral neuropathy in HTLV-1 infected individuals without tropical spastic paraparesis/ HTLV-1-associated myelopathy. J Neurol. 2004;251:877-81.
68. Gonzalez-Duarte A, Robinson-Papp J, Simpson D. Diagnosis and management of HIV-associated neuropathy. Neurol Clin. 2008;26:821-32, x.
69. Hoke A, Cornblath D. Peripheral neuropathies in HIV infection. Suppl Clin Neurophysiol. 2004;57:195-210.
70. McArthur J, Brew B, Nath A. Neurological complications of HIV infection. Lancet Neurol. 2005;4:543-55.
71. Morgello S, Estanislao L, Simpson D, et al. HIV-associated distal sensory polyneuropathy in the era of HAART: the Manhattan HIV Brain Bank. Arch Neurol. 2004;61:546-51.
72. Zehender G, De Maddalena C, Osio M, et al. High prevalence of HTLV-2 infection in patients affected by HIV-associated predominantly sensory polyneuropathy. J Infect Dis. 1995;172:1595-8.
73. Beilke M, Theall K, O'Brien M, et al. Clinical outcomes and disease progression among patients coinfected with HIV and HTLV types 1 and 2. Clin Infect Dis. 2004;39:256-63.
74. Tournier-Lasserve E, Gout O, Gessain A, et al. HTLV-1, brain abnormalities on magnetic resonance imaging, and relation with multiple sclerosis. Lancet. 1987;2:49-50.
75. Kira J, Fujihara K, Itoyama Y, Goto I, Hasuo K. Leukoencephalopathy in HTLV-1-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci. 1991;106:41-9.
76. Cartier L, Gormaz A, Araya F, Castillo J. Cognitive function in progressive spastic paraparesis associated to HTLV-1: A preliminary study. Rev Chil Neuro-Psiquiat. 1992;30:241-6.
77. Cartier L, Gormaz A. [Subcortical dementia in HTLV-I tropical spastic paraparesis. Study of 43 cases]. Rev Med Chil. 1999;127:444-50.
78. Castillo J, Camposano S, Cartier L, Gormaz A, Quevedo F. Event related potentials in progressive spastic HTLV-1 positive and negative paraparesis. Rev Chil Neuro-Psiquiat. 1995;33:45-50.
79. Cartier L, Gormaz A, Kleinsteuber K, Ramirez E, Galeno H. [New form of subcortical dementia: encephalopathy due to infection with HTLV-1. Clinical case]. Rev Med Chil. 1997;125:209-13.
80. Cartier L, Araya F, Castillo J, et al. Subacute encephalomyelopathy associated with HTLV-I: pseudobulbar paralysis and mental deterioration. Neurology. 1990;40(Suppl 1):238.
81. Lycke J, Svennerholm B, Svenningsson A, Horal P, Nordqvist-Brandt E, Andersen O. Possible association of HTLV-1 infection and dementia. Acta Neurol Scand. 1993;88:199-203.
82. Fukushima T, Ikeda T, Uyama E, Uchino M, Okabe H, Ando M. Cognitive event-related potentials and brain magnetic resonance imaging in HTLV-1 associated myelopathy (HAM). J Neurol Sci. 1994;126:30-9.
83. Kira J, Hamada T, Kawano Y, Okayama M, Yamasaki K. An association of HTLV-1 infection with vascular dementia. Acta Neurol Scand. 1997; 96:305-9.
84. Sulkava R, Korpela J, Erkinjuntti T. No antibodies to HTLV-1 and HIV in patients with dementia in Finland. Acta Neurol Scand. 1987;76:155-6.
85. Silva M, Mattos P, Alfano A, Araujo A. Neuropsychological assessment in HTLV-1 infection: a comparative study among TSP/HAM, asymptomatic carriers, and healthy controls. J Neurol Neurosurg Psychiatry. 2003;74:1085-9.
86. Isono T, Ogawa K, Seto A. Antiviral effect of zidovudine in the experimental model of adult T cell leukemia in rabbits. Leuk Res. 1990; 14:841-7.
87. Gout O, Gessain A, Iba-Zizen M, et al. The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol. 1991;238:108-9.
88. Sheremata W, Benedict D, Squilacote D, Sazant A, DeFreitas E. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology. 1993;43:2125-9.
89. Taylor G, Hall S, Navarrete S, et al. Effect of lamivudine on HTLV-1 DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol. 1999;73:10289-95.
90. Taylor G, Goon P, Furukawa Y, et al. Zidovudine plus lamivudine in HTLV-1-associated myelopathy: a randomised trial. Retrovirology. 2006;3:63.